W
WAVEMAN · COMPANY
KYTX · Kyverna Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

KYTX

Kyverna Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001994702
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
68
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
68 funds added or opened last quarter
more than 53% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
13.2% of shares outstanding short · 8.7 days to cover · settled 2026-07-31
more than 87% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
68 funds added or opened positions in the latest 13F quarter, of 122 holders.
3 clinical trials were terminated, suspended or withdrawn in the last 90 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +129.8%
+129.8%12M
+0%+71%+142%+213%2025-092025-102025-122026-032026-052026-072026-09 2025-12-18 · SEIDENBERG BETH C bought $1,000.0K2025-12-18 · Westlake BioPartners Opportunity Fund I, L.P. bought $1,000.0K2025-12-15 · Walker Karen Marie sold $292.8K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 68 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Kyverna Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
SEIDENBERG BETH C
Director
BUY
2025-12-18
133,333.0
$1,000.0K
Westlake BioPartners Opportunity Fund I, L.P.
—
BUY
2025-12-18
133,333.0
$1,000.0K
Walker Karen Marie
Chief Technology Officer
SELL
2025-12-15
23,998.0
$292.8K
Vida Ventures GP III, L.L.C.
—
BUY
2024-02-12
252,553.0
$5.6M
Vida Ventures GP III, L.L.C.
—
BUY
2024-02-12
583.0
$12.8K
8 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 3 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
GordonMD Global Investments LP
4,244,818.0 sh
$37.8M
GILEAD SCIENCES, INC.
4,126,119.0 sh
$36.8M
BlackRock, Inc.
3,134,807.0 sh
$27.9M
Bain Capital Life Sciences Investors, LLC
2,885,000.0 sh
$25.7M
AIGH Capital Management LLC
2,795,797.0 sh
$24.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Simplify Propel Opportunities ETF
$1.5M POSITION · AS OF 2026-03-31
2.2%
Ultra-Small Company Fund
$966.6K POSITION · AS OF 2026-03-31
1.1%
WesMark Small Company Fund
$951.9K POSITION · AS OF 2026-03-31
0.6%
Ultra-Small Company Market Fund
$250.3K POSITION · AS OF 2026-03-31
0.2%
EQ/T.Rowe Price Health Sciences Portfolio
$198.2K POSITION · AS OF 2026-03-31
0.1%
Health Sciences Trust
$277.1K POSITION · AS OF 2026-03-31
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 7 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 2
1 ACTIVE
1
Not applicable
1 ACTIVE
4
Multi-phase
1 ACTIVE
What changed recently
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision.
PHASE1,PHASE2
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision.
PHASE1,PHASE2
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Completion moved 2026-03 → 2026-06-16
PHASE1,PHASE2
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision
PHASE1,PHASE2
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-12
OPERATING INCOME$-169.8M$-142.6M$-62.4M
NET INCOME$-161.3M$-127.5M$-60.4M
EPS (DILUTED)-3.64-3.33-89.61
OPERATING CASH FLOW$-153.7M$-114.2M$-52.4M
CASH$124.1M$96.6M$34.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →